The Medicines Company (MDCO) reported quarterly earnings results on Monday, May-9-2016. The company reported $-1.03 earnings per share for the quarter, missing the analyst consensus estimate by $-0.37. Analysts had a consensus of $-0.66. The company posted revenue of $50.30 million in the period, compared to analysts expectations of $49.11 million. The company’s revenue was down -54.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.08 EPS.
Many Wall Street Analysts have commented on The Medicines Company. Company shares were Reiterated by Chardan Capital Markets on Mar 21, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $50 .
The Medicines Company opened for trading at $35.24 and hit $36.35 on the upside on Friday, eventually ending the session at $36.2, with a gain of 3.46% or 1.21 points. The heightened volatility saw the trading volume jump to 13,47,504 shares. Company has a market cap of $2,520 M.
In a different news, on Mar 8, 2016, William Bernard O’connor (Chief Financial Officer) sold 8,617 shares at $34.51 per share price. According to the SEC, on Mar 8, 2016, Armin M Kessler (director) sold 8,100 shares at $34.82 per share price. On Nov 16, 2015, Robert G. Savage (director) sold 5,000 shares at $39.34 per share price, according to the Form-4 filing with the securities and exchange commission.
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products are: Angiomax (bivalirudin) Cleviprex (clevidipine) injectable emulsion Minocin (minocycline) for injection Orbactiv (oritavancin) PreveLeak and Recothrom Thrombin topical (Recombinant). The Company’s products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States cangrelor IONSYS (fentanyl iontophoretic transdermal system) Raplixa formerly referred to as Fibrocaps and RPX-602. The Company’s four research and development product candidates include ABP-700 ALN-PCSsc Carbavance and MDCO-216. The Company also develops ABP-700 an intravenous anesthetic which is in Phase I of clinical studies.